Integrating Bulk RNA-Seq and scRNA-Seq Analyses with Machine Learning to Predict Platinum Response and Prognosis in Ovarian Cancer

Integrating bulk RNA-seq and scRNA-seq analyses with machine learning to predict platinum response and prognosis in ovarian cancer

Platinum-based therapy is an integral part of the standard treatment for ovarian cancer. However, despite extensive research spanning several decades, the identification of dependable predictive biomarkers for platinum response in clinical practice has proven to be a formidable challenge. Recently, the development of single-cell technology has enabled more precise investigations into the heterogeneity of cancer. In this study, we isolated cancer…

Win for Added Relacorilant in Platinum-Resistant Ovarian Cancer

(MedPage Today) -- CHICAGO -- Combining investigational relacorilant with nab-paclitaxel (Abraxane) improved progression-free survival (PFS), and demonstrated a clinically meaningful trend towards an overall survival (OS) benefit, in patients...

ROSELLA Trial Offers New Insight Into Global Treatment Strategies for Ovarian Cancer: Brian Slomovitz, MD

Brian Slomovitz, MD, of Mount Sinai Medical Center, compares relacorilant plus nab-paclitaxel with existing treatments for platinum-resistant ovarian cancer and highlights the ROSELLA trial’s global scope.

ASCO 2025: what went down this week?

Discover the major highlights from ASCO, according to researchers and drug developers who attended the convention. The post ASCO 2025: key highlights in cancer therapeutics appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and cle…

Frontiers | Multimodal data integration with machine learning for predicting PARP inhibitor efficacy and prognosis in ovarian cancer

BackgroundPoly(ADP)-ribose polymerase inhibitors (PARPi) have brought a significant breakthrough in the maintenance treatment of ovarian cancer. However, bey...

ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer

Corcept Therapeutics’ relacorilant, a selective glucocorticoid receptor antagonist (SGRA), is emerging as a novel therapeutic candidate in the treatment of ovarian cancer, an area challenged by limited treatment options due to eventual recurrence and resistance to the mainstay platinum-based chemotherapies.The post ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer appeared first on Clinical Tria…